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Clinical Relevance of Rehospitalizations for Unstable Angina and
Unplanned Revascularization Following Acute Myocardial Infarction
Supriya Shore, MD, MSCS; Kim G. Smolderen, PhD; John A. Spertus, MD, MPH; Kevin F. Kennedy, MS; Philip G. Jones, MS;
Zhenxiang Zhao, PhD; Tracy Y. Wang, MD, MHS, MSc; Suzanne V. Arnold, MD, MHA
Background-—Rehospitalizations following acute myocardial infarction for unplanned coronary revascularization and unstable
angina (UA) are often included as parts of composite end points in clinical trials. Although clearly costly, the clinical relevance of
these individual components has not been described.
Methods and Results-—Patients enrolled in a prospective, 24-center, US acute myocardial infarction registry were followed for
1 year after an acute myocardial infarction for rehospitalizations, that were independently adjudicated by experienced
cardiologists. Patients who did and did not experience UA or revascularization rehospitalization were propensity matched using
greedy matching. Among 3283 patients with acute myocardial infarction who were included, mean age was 59 years, 33% were
female, and 70% were white. Rehospitalization rates for UA and unplanned revascularization at 1 year were 5.0% and 4.1%,
respectively. After propensity matching, we included 2433 patients in the UA rehospitalization group and 2410 in the unplanned
revascularization group. Using weighted proportional hazards Cox regression, there was no significant association between a
rehospitalization for UA and 5-year all-cause mortality (9.6% versus 13.8%; adjusted hazard ratio 0.87, 95% CI 0.60–1.16). Patients
rehospitalized for unplanned revascularization had a lower 5-year mortality risk (7.0% versus 15.1%; hazard ratio 0.68, 95% CI 0.50–
0.92) compared with those without such rehospitalizations. Nevertheless, patients with UA and unplanned revascularization had a
substantially greater hazard of subsequent rehospitalizations compared with patients without such events (UA: hazard ratio 4.36,
95% CI 3.48–5.47; revascularization: hazard ratio 4.38, 95% CI 3.53–5.44).
Conclusions-—Rehospitalizations for UA and unplanned revascularization in the year after an acute myocardial infarction are
associated with higher risks of subsequent rehospitalizations but not with mortality. ( J Am Heart Assoc. 2016;5:e003129 doi:
10.1161/JAHA.115.003129)
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R ehospitalizations after acute myocardial infarction (AMI)have attracted major attention by payors and regulators
in recent years and now are considered a marker of poor health
care quality.1 Although the economic implications of rehospi-
talizations are indisputable,2 little is known about their clinical
impact on patients. In particular, the association between
these readmissions and subsequent mortality and morbidity is
not known. Given that rehospitalizations for unstable angina
(UA) and coronary revascularization are often included as parts
of composite end points in clinical trials, better defining their
clinical importance in terms of mortality and recurrent events
is important.3,4 Underscoring the heterogeneity of clinical
significance for different components of composite clinical end
points, a recent study asking clinical trialists and patients to
rank individual components of composite end points in terms
of their perceived importance found that revascularizations
and rehospitalizations were considered less important than the
other end points, such as mortality, stroke, and myocardial
infarction.3,5 As such, a better understanding of the clinical
importance of rehospitalizations for UA and revascularization
could inform the design of composite end points and support
the interpretation of studies using these events as part of their
primary outcome. To address this gap in knowledge, we sought
to examine the association between rehospitalizations for
recurrent ischemic coronary events and subsequent mortality
and rehospitalizations.
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The analytic cohort for this study was derived from the
TRIUMPH (Translational Research Investigating Underlying
Disparities in Acute Myocardial Infarction patients’ Health
Status) registry. TRIUMPH is a prospective multicenter
observational registry that enrolled 4340 AMI patients from
24 US medical centers between April 11, 2005, and
December 31, 2008.6 Eligible patients were aged ≥18 years
with a diagnosis of AMI within 24 hours of admission. AMI
was defined as elevated cardiac biomarkers and additional
clinical evidence supporting the diagnosis of AMI, including
electrocardiographic ST changes or clinical signs and symp-
toms of ischemia. Baseline data were obtained through chart
abstraction and a standardized in-person interview by trained
research staff during the index AMI admission. Institutional
review board approval was obtained at each participating
center, and all patients signed an informed consent for
baseline and follow-up interviews. Patients were also asked to
consent to medical record abstractions of hospitalizations
over the next year following the index AMI.
Follow-up and Definition of Exposure
Follow-up telephone interviews were attempted for all
survivors at 1, 6, and 12 months after the index AMI. During
these follow-up interviews, patients were asked to report
interval events (eg, procedures, diagnostic tests, hospitaliza-
tions, and outpatient visits) since their last study contact. If a
patient reported being hospitalized since the previous inter-
view and had consented to medical record review, records of
that hospitalization were obtained to classify cardiovascular
events. Chart abstractions were sent to 2 cardiologists who
independently classified the reason for hospitalization. If there
was disagreement between the 2 cardiologists, the record
was adjudicated by a third cardiologist; if disagreement
persisted, up to 5 cardiologists independently reviewed the
charts until consensus was obtained. Patients who did not
consent to medical record review or those for whom records
were unable to be obtained were excluded from the study to
avoid misclassification of rehospitalizations.
Our primary exposure variables were rehospitalizations for
UA and unplanned revascularization. UA was defined, based
on guidelines, as a hospitalization due to symptoms sugges-
tive of ischemia that was of new onset, that was increasing in
severity (ie, more frequent, longer in duration, or lower in
threshold), or that occurred at rest.7 Hospitalizations with
ischemic symptoms and biomarker positivity or ST-segment
elevations on ECG were excluded. An unplanned revascular-
ization was defined as a revascularization procedure that was
not planned at the time of the index AMI admission and that
was not performed in the setting of a recurrent AMI (to avoid
examining the clinical impact of recurrent AMIs). All staged
percutaneous coronary interventions (PCIs) and elective
coronary artery bypass grafting (CABG) surgeries performed
within 1 month of the index AMI were excluded. Because both
cohorts were set up separately, if a patient had admissions for
both unplanned revascularization and UA, they were included
in both cohorts.
Outcomes
Our outcomes of interest included all-cause mortality and
rehospitalization. Mortality was assessed over 5 years follow-
ing the exposure event through a query of the Social Security
Death Master File. Rehospitalization was defined as the first
rehospitalization after the exposure event (ie, the UA or
unplanned revascularization rehospitalization) that occurred
within 1 year following the index AMI. These events were also
determined through chart abstractions performed by inde-
pendent cardiologists, as described earlier. In addition, we
also examined time to first cardiovascular-cause rehospital-
ization, which included admission for AMI, UA, heart failure,
stroke, coronary revascularization, or other cardiovascular
procedures (eg, implantable cardioverter-defibrillator implan-
tation, peripheral arterial procedures). A longer follow-up
period for mortality was selected to increase the number of
events and thus to improve statistical efficacy. As part of the
TRIUMPH registry, however, follow-up data on rehospitaliza-
tion was collected for only the 1 year after index AMI;
therefore, longer term rehospitalization data were unavailable.
Covariates for Propensity Matching
We included a wide range of variables based on prior literature
or clinical judgment to generate propensity-matched cohorts.
Demographic covariates included age; sex; race; and educa-
tional, marital, insurance, and work status. Clinical covariates
included body mass index, prior AMI (before the AMI at index
hospitalization), prior CABG, prior stroke or transient ischemic
attack, prior stable angina, cancer, diabetes mellitus, hyper-
tension, hypercholesterolemia, peripheral vascular disease,
chronic kidney disease, dialysis, chronic heart failure, chronic
lung disease, family history of coronary artery disease,
depression, and baseline health status (as measured by
Seattle Angina Questionnaire angina frequency and quality of
life scores8 and Short Form 12 physical and mental compo-
nent summary scores9). Index hospitalization clinical covari-
ates included initial systolic blood pressure, initial heart rate,
ST-segment elevations on ECG, left ventricular systolic
dysfunction (ejection fraction <40%), Global Registry of Acute
Coronary Event discharge risk score,10 and highest serum
troponin level. Finally, treatment characteristics during index
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AMI hospitalization included in-hospital PCI and CABG and
medications at admission and at discharge, including aspirin,
beta blockers, statins, angiotensin antagonists, thienopyridi-
nes, and insulin.
Statistical Analysis
To account for differences in characteristics of patients with
and without UA or unplanned revascularization rehospitaliza-
tion, we needed to identify patients without UA or revascu-
larization who were similar to those who experienced them.
This was accomplished through the creation of propensity
scores with UA and unplanned revascularization as the
outcomes of interest. To do this, we calculated 2 propensity
scores: (1) to be hospitalized for UA and (2) to be hospitalized
for unplanned revascularization after AMI. Propensity score
models included the covariates described earlier. Any missing
data for baseline variables were imputed by sequential
regression imputation incorporating all baseline variables.
Site of initial hospitalization was included as a fixed effect to
account for clustering of patients by site.
We then matched patients with UA rehospitalization to
those without an admission for UA using greedy matching on
the logit of the propensity score. The caliper width was
chosen as 0.2 times the pooled standard deviation of the logit
propensity scores for the groups. The same approach was
used to develop propensity-matched cohorts for those with
and without unplanned coronary revascularization; therefore,
2 matched cohorts were created: (1) those with and without a
UA rehospitalization and (2) those with and without a
revascularization rehospitalization. Each patient with an
exposure (ie, rehospitalization for UA or unplanned revascu-
larization) was matched to many patients without exposure.
The models were conditional on the matched pair, with
weights developed from the number of nonexposures that
were matched in a pair, so as not to overweight any individual
pairing.11 Balance of baseline characteristics between
matched cohorts was examined before and after matching
using absolute standardized differences, with <10% consid-
ered good balance between groups.12
We then used these matched cohorts to examine the
association of UA and revascularization hospitalizations with
subsequent mortality and rehospitalization. For each of these
analyses, time zero for the exposure groups (ie, patients with
UA or unplanned revascularization readmissions) was dis-
charge from the first UA or revascularization event. Time zero
for the control groups (ie, patients without UA or unplanned
revascularization readmission) was also matched such that it
was the same date as patients in the exposure group.
Subsequently, the patients were tracked forward from that
time point for subsequent death or rehospitalization. Cox
proportional hazards models were stratified by matched sets
and used to examine this association. The proportional
hazards assumption was evaluated and found to be valid for
all models. Statistical significance was defined by P<0.05, and
all analyses were performed with SAS version 9.2 (SAS
Institute) and R version 2.11.1 (R Foundation for Statistical
Computing).
Enrolled in TRIUMPH 
(n=4340) 
Death in the first month (n=71) 
Patients with complete data on 
rehospitalizations available for 
adjudication 







Lost to follow-up (n=637) 
Missing rehospitalization data (n=349) 
Unable to be matched  
(n=873) 
Unable to be matched  
(n=850) 
Figure 1. Study population. UA indicates unstable angina.
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Data (n=986) P Value
Age, y (meanSD) 59.412.0 57.513.2 <0.001





Married 53.4 44.8 <0.001
High school education 79.9 77.8 0.16
Lack of insurance 19.3 25.0 <0.001
Currently employed 50.6 45.1 0.003
Dyslipidemia 49.4 48.0 0.43
Hypertension 66.1 67.7 0.34
Prior CVA/TIA 6.7 7.7 0.28
Peripheral vascular disease 4.7 4.6 0.90
Diabetes mellitus 29.0 35.8 <0.001
Prior myocardial infarction 19.6 24.8 <0.001
Prior angina 14.3 17.0 0.03
Prior CABG 10.6 13.6 0.01
Prior PCI 19.1 21.4 0.12
Chronic kidney disease 6.3 10.4 <0.001
Chronic lung disease 7.0 7.8 0.40
Chronic heart failure 6.9 13.6 <0.001
History of malignancy 7.3 6.7 0.53
Current smoker 38.4 43.2 0.01
Depression 7.5 8.6 0.26
BMI, meanSD 29.66.5 29.56.5 0.64
Family history of CAD 74.7 71.3 0.04
Initial systolic blood pressure, mm Hg (meanSD) 14330 14431 0.52
Initial heart rate, bpm (meanSD) 8222 8523 <0.001
STEMI 44.6 37.6 <0.001
In-hospital CABG 10.1 6.8 0.002
In-hospital PCI 67.0 59.8 <0.001
GRACE 6-month score, meanSD 99.928.9 100.933.1 0.36
Highest serum troponin level, meanSD 29.375.6 25.761.4 0.17
Aspirin at discharge 95.0 92.3 0.001
Beta blocker at discharge 90.7 90.2 0.61
Statin at discharge 88.5 87.1 0.26
ACEI/ARB at discharge 74.6 74.7 0.91
Data are shown as percentages except as noted. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; bpm, beats per minute;
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CVA, cerebrovascular accident; GRACE, Global Registry of Acute Coronary Event; PCI, percutaneous coronary
intervention; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischemic attack.
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Table 2. Baseline Characteristics of Propensity-Matched Cohorts












Age, y (meanSD) 58.111.6 59.311.9 3.44 59.410.7 59.611.9 3.11
Female sex 46.4 34.2 3.60 35.4 33.1 6.02
Race
White 65.7 71.9 2.98 78.8 72.8 2.5
Black 23.6 22.3 4.76 16.8 21.5 1.5
Other 10.7 5.8 12.99 4.4 5.7 4.9
Married 43.6 53.9 0.56 54.0 54.6 0.91
High School Education 85.0 82.6 6.30 87.6 82.2 2.29
Lack of insurance 24.3 17.7 2.46 17.7 16.9 4.13
Currently employed 42.9 51.6 3.01 46.0 51.9 0.54
Dyslipidemia 51.4 49.8 1.45 48.7 50.4 0.03
Hypertension 72.1 65.3 1.11 64.6 65.9 2.03
Prior CVA/TIA 7.9 6.4 5.3 5.3 6.4 4.52
Peripheral vascular disease 8.6 4.3 2.47 6.2 4.7 1.46
Diabetes mellitus 37.1 28.5 5.40 30.1 27.7 3.97
Prior myocardial infarction 22.9 18.8 1.17 17.7 18.7 0.63
Prior CABG 20.7 10.9 2.07 15.9 10.7 2.30
Prior PCI 29.3 19.2 3.33 23.0 19.1 1.30
Chronic kidney disease 7.1 6.0 0.11 4.4 5.1 0.66
Chronic lung disease 7.1 6.0 1.95 7.1 7.0 3.03
Chronic heart failure 7.1 6.3 4.17 4.4 5.6 1.50
Current smoker 42.1 37.6 2.49 29.2 36.7 3.77
Depression 10.7 8.2 0.34 5.3 7.5 0.91
BMI, meanSD 29.57.5 29.76.4 2.21 29.06.2 29.66.5 0.14
Systolic blood pressure, mm Hg
(meanSD)
14230 14330 1.87 14130 14330 0.71
Heart rate, bpm (meanSD) 8221 8122 1.34 7919 8122 0.24
STEMI 42.9 46.5 2.22 52.2 46.6 1.05
In-hospital CABG 3.6 6.4 0.23 2.7 8.4 5.35
In-hospital PCI 78.6 72.4 2.12 80.5 69.7 4.81
GRACE score, meanSD 95.728.2 98.628.2 0.79 97.525.6 99.428.2 2.87
Peak troponin, ng/dL 40.6138.2 31.074.1 4.45 39.1140.9 29.869.8 1.36
Aspirin at discharge 94.3 94.7 1.94 95.6 95.5 1.06
Beta blocker at discharge 85.7 91.1 0.81 89.4 90.8 0.002
Statin at discharge 90.0 88.1 1.14 89.4 88.6 1.15
ACEI/ARB at discharge 82.9 76.8 2.82 83.2 75.4 6.61
Data are shown as percentages except as noted. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; bpm, beats per
minutes; CABG, coronary artery bypass grafting; CVA, cerebrovascular accident; GRACE, Global Registry of Acute Coronary Event; PCI, percutaneous coronary intervention; Revasc,
revascularization; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischemic attack.
DOI: 10.1161/JAHA.115.003129 Journal of the American Heart Association 5























Between April 2005 and December 2008, 4340 patients with
an AMI were enrolled in the TRIUMPH registry. We excluded
patients who died within the first month and never had the
opportunity for follow-up (n=71). Of the remaining 4269
patients, 986 patients (23%) were subsequently excluded due
to missing data, which was caused by loss to follow-up
(n=637), lack of patient consent for medical chart review
(n=77), or hospitals not honoring patients’ medical record
release forms (n=272). The final analytic cohort consisted of
3283 patients (Figure 1). The mean age of the patients
included in our matched cohort was 59 years, 33% were
female, and 70% were white. The comorbidity burden was
high, with 29% of patients having diabetes mellitus, 20%
having prior myocardial infarction, 19% having prior PCI, and
11% having prior CABG. Table 1 shows the baseline charac-
teristics of patients included in the analytic cohort compared
with those with missing data. Patients with missing data
Figure 2. Assessment of balance before and after propensity matching between patients with and without
unstable angina rehospitalizations (A) and unplanned coronary revascularization rehospitalizations (B).
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ArrKillip, Killip
class on arrival; BL, baseline; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass
grafting; CAD, coronary artery disease; CVA, cerebrovascular accident; DC, discharge; GRACE, Global
Registry of Acute Coronary Event; LV, left ventricular; max, maximum; MI, myocardial infarction; Mo, month;
PCI, percutaneous coronary intervention; Pt, patient; ReqRx, requiring treatment; SAQ, Seattle Angina
Questionnaire; SF-12, Short Form 12; TIA, transient ischemic attack.
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tended to be younger, were more likely to be female and of
nonwhite race, and had more comorbidities compared with
patients in the analytic cohort.
Among 3283 patients who were followed for 1 year after
AMI, 140 patients (Kaplan–Meier estimate of 5.0%) were
rehospitalized due to UA, with a median time to event of
4.1 months (interquartile range 1.2–7.3 months), and 113
patients (Kaplan–Meier estimate of 4.1%) were rehospitalized
for unplanned coronary revascularizations, with a median time
to event of 3.6 months (interquartile range 1.5–7.4 months).
There were 56 patients who were admitted with both of these
events and thus were included in both cohorts. The propen-
sity-matched cohorts for UA and unplanned coronary revas-
cularization included 2433 and 2410 patients, respectively.
There were no significant differences between the matched
cohorts for either UA or revascularization, as suggested by
small standardized differences between the groups (Table 2).
Figure 2A shows the balance between patients with and
without UA rehospitalization, and Figure 2B shows the
balance between patients with and without unplanned
coronary revascularization before and after propensity score
matching.
All-Cause Mortality
Among patients in the entire cohort, the Kaplan–Meier
estimated 5-year mortality rates were 13.7% among patients
with UA rehospitalization compared with 14.6% among
patients without UA rehospitalizations (unadjusted hazard
ratio [HR] 0.81, 95% CI 0.62–1.07). The 5-year mortality rates
Figure 2. Continued
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among patients with unplanned revascularization readmis-
sions were 9.7% compared with 15.2% in those without such
readmissions (unadjusted HR 0.61, 95% CI 0.45–0.82).
Among patients in the propensity-matched cohorts, the
Kaplan–Meier estimated 5-year mortality rates (after the index
rehospitalization event) were 9.6% versus 13.8% in patients
with versus without a UA rehospitalization, respectively, and
7.0% versus 15.1% in patients with versus without unplanned
revascularization rehospitalizations, respectively (log-rank
P=0.25 for UA rehospitalizations and P=0.003 for unplanned
coronary revascularization) (Figure 3A and 3B). The hazard for
all-cause mortality did not differ between patients with and
without UA rehospitalizations (HR 0.84, 95% CI 0.63–1.13).
Patients with unplanned revascularization, however, were less
likely to die over the following 5 years compared with those
without revascularization (HR 0.62, 95% CI 0.45–0.84)
(Table 3).
Rehospitalizations
In the year following index AMI, 53.2% of patients with UA
readmissions had at least 1 subsequent rehospitalization
compared with 15.3% of patients without UA readmissions
(log-rank P<0.001) (Figure 4A). In the adjusted analyses, we
observed a 3.99 fold increased hazard of subsequent
rehospitalization (95% CI 2.97–5.35). Similarly, there was a
significant association between UA rehospitalization and
subsequent first cardiovascular rehospitalization (36.8% ver-
sus 6.4%; HR 7.66, 95% CI 5.00–11.75). The most common
reasons for rehospitalizations among patients who had a prior
UA rehospitalization were repeated UA, noncardiac chest
pain, and heart failure (Table 4).
Among patients with unplanned coronary revascularization
admission, 58.2% of patients had at least 1 subsequent all-
cause rehospitalization in the year following index AMI (after
the unplanned revascularization) compared with 17.1% of
patients without unplanned revascularization readmissions
(log-rank P<0.001) (Figure 4B). In adjusted analyses, we
observed a 4.27-fold increased hazard of subsequent rehos-
pitalization (95% CI 3.23–5.66). In addition, there was also a
significant association between unplanned coronary revascu-
larization and subsequent first cardiovascular rehospitaliza-
tion (27.6% versus 6.1%; HR 3.87, 95% CI 2.56–5.86). The
most common reasons for rehospitalizations among patients
who had a prior revascularization rehospitalization were UA
and noncardiac chest pain (Table 4).
Discussion
In a large multicenter registry, we found that rehospitaliza-
tions for UA and unplanned coronary revascularization within
the first year after an AMI were not associated with a higher
risk of mortality. Nevertheless, these events were associated
with a higher hazard for subsequent rehospitalizations, both
all-cause and cardiovascular. These findings suggest that a
rehospitalization for UA or unplanned revascularization after
an AMI is a marker for patients at very high risk of repeated
A
B
Figure 3. Kaplan–Meier curves for probability of 5-year mortal-
ity in the propensity-matched cohorts for UA rehospitalizations (A)
and unplanned coronary revascularization (B). UA indicates
unstable angina.
Table 3. Association Between Rehospitalizations for











All-cause mortality 0.81 (0.62–1.07) 0.61 (0.45–0.82)
Rehospitalization
(all-cause)
3.99 (2.97–5.35) 4.27 (3.23–5.66)
Rehospitalization
(cardiac)
6.40 (5.00–11.75) 3.87 (2.56–5.86)
HR, hazard ratio.
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hospitalizations. Further work is needed to illuminate strate-
gies that can mitigate this risk to minimize the economic
impact of these rehospitalizations,2 even if they are not
associated with increased mortality.
Given the lack of proven clinical impact of UA and
revascularization rehospitalizations, prior studies have raised
concerns regarding the use of rehospitalizations both as a
quality metric and as an outcome within composite end points
for clinical trials.3,4 Part of this concern stems from the
knowledge that these events are, in part, determined by the
actions of clinicians and patients rather than by the disease
process alone and may introduce substantial bias when used
as an outcome in clinical trials.13 In an analysis from the
Synergy Between PCI With Taxus and Cardiac Surgery
(SYNTAX) trial, for example, CABG patients who required
repeated revascularization had much worse angina and health
status compared with PCI patients who had a repeat
procedure, suggesting that there was a different threshold
for reintervention depending on the patient’s prior revascu-
larization procedure.14 In contrast, outcomes such as death or
myocardial infarctions, which are objective and quantifiable,
are not subject to these potential biases. Further challenging
the importance of these events, a recent study that asked
patients and trialists to rank the importance of the compo-
nents of composite end points used in cardiovascular clinical
trials, rehospitalizations and revascularizations were ranked
as least important by both patients and trialists.3,5 Our study
confirms that these events are likely not as clinically relevant
as events such as myocardial infarctions and strokes, given
that we did not find UA and revascularization events to be
associated with an increased risk of mortality. Our study,
however, provides new insights into the clinical implications
of such rehospitalizations, particularly in identifying a group of
patients at high risk for recurrent rehospitalizations. Given our
prior work showing that UA and coronary revascularization
rehospitalizations are also associated with impaired quality of
life,15 interventions to prevent these rehospitalizations or to
at least break the cycle of recurrent rehospitalizations are
needed.
Understanding how to prevent recurrent rehospitalizations
is of key importance to hospitals, which are being held
increasingly accountable for these rehospitalizations. Our
previous work has shown that the predictors of UA and
Table 4. One-Year Kaplan–Meier Estimates for Readmission
Etiologies











Emergent 84.8 77.7 88.9 86.8
Noncardiac 34.9 57.6 42.2 54.5
Cardiac 65.1 42.4 57.8 45.5
Demand ischemia with
positive enzymes
0 1.3 0 0.8
UA with ischemia 4.5 0 2.2 0.4
UA or chest pain without
ischemia
21.2 0 20.0 11.5
Stable angina 1.5 3.5 2.2 0.8
Noncardiac chest pain 15.8 17.5 20.0 22.4
Subacute stent thrombosis 0 0 0 0.8
Heart failure 15.8 14.9 6.7 12.3
Arrhythmia 3.0 4.4 2.2 2.1
Bleeding 1.5 0.4 2.2 3.4
Elective cardiac
catheterization
3.0 8.3 2.2 1.7
Syncope 1.5 2.2 0 2.1
Other cardiac reason 3.0 2.6 2.2 4.3
Data are shown as percentages. Revasc indicates revascularization; UA, unstable angina.




Figure 4. Kaplan–Meier curves for probability of all-cause
rehospitalizations in the propensity-matched cohorts for UA
rehospitalizations (A) and unplanned coronary revascularization
(B). UA indicates unstable angina.
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revascularization rehospitalizations after an AMI fall into 1 of
2 categories: disease burden or psychosocial factors.16 It is
not surprising that patients with a higher burden of cardio-
vascular disease (eg, prior CABG, prior PCI, peripheral artery
disease) are more likely to be rehospitalized for recurrent
cardiac events; however, knowing how to differentially affect
disease progression in these high-risk patients is difficult
because aggressive secondary prevention efforts are indi-
cated in all post-AMI patients. The second group of factors
that are associated with rehospitalizations (eg, younger age,
female sex, uninsured, nonworking status) may help identify a
group of patients for whom multidisciplinary efforts to reduce
rehospitalizations could be useful. Interventions other than
secondary prevention (eg, exercise, stress reduction, social
work visits) might be useful in preventing the cycle of
rehospitalizations, could have important economic and health
status implications, and should be prospectively tested.
Our results also have an important implication for inter-
preting clinical trial results that frequently use composite
clinical end points. Such composite end points frequently
incorporate rehospitalizations due to UA and unplanned
repeat coronary revascularizations. Composite end points
help increase statistical efficiency of trials and decrease
duration of follow-up needed for such trials by increasing the
number of clinical events.17 This has become increasingly
more important as hard events such as mortality after AMI
continue to decline, with the result that several trials reach
statistical significance on their composite simply secondary to
decreases in rehospitalization or revascularization rates.13
Consequently, interpreting such trial results is challenging
because the clinical impact of these events has not been
established, making the risk–benefit balance difficult to be
appropriately weighed.17 Accordingly, our study results help
establish the lack of clinical impact of these end points and,
we believe, will help in interpreting clinical trial results.
The results of our study should be interpreted in the
context of several potential limitations. First, we included only
patients for whom all rehospitalizations were available for
adjudication, and that limited our sample size and may have
limited the generalizability of our results. Because the
abstraction process was triggered by self-reporting of rehos-
pitalizations, this likely resulted in underreporting of events.
Nevertheless, the adjudication process for identifying the UA
and revascularization rehospitalizations increased the speci-
ficity of the defined hospitalizations, ensuring that we were
examining the intended associations. Second, we were unable
to provide longer term data on rehospitalizations beyond
1 year of follow-up because they were not collected as part of
the registry. Nonetheless, we provided 5-year data on
mortality, and that is comparable to the standard follow-up
period for most clinical trials. Finally, as with all other
observational studies, we could not prove a causal association
between UA and revascularization rehospitalizations and
subsequent rehospitalizations, and the issue of unmeasured
confounding remains. We believe that such rehospitalizations
may be markers, rather than mediators, of subsequent events.
In conclusion, we found that patients who were rehospi-
talized for UA or unplanned coronary revascularization after
an AMI were not at increased risk for subsequent mortality
compared with patients without these rehospitalizations.
These patients, however, were much more likely to be
subsequently rehospitalized at some point over the same 12-
month period. These findings highlight that rehospitalizations
for UA and unplanned coronary revascularizations are
economically important and may support the use of rehos-
pitalizations as an end point in clinical trials. More importantly
they suggest that such rehospitalizations in the first year after
AMI are markers of a cohort of patients at high risk for
recurrent rehospitalizations. Future work is needed to under-
stand how to break these cycles of rehospitalization, whether
through aggressive secondary prevention efforts or potential
psychosocial interventions that address noncardiac factors.
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